ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

KVB K V Pharma CL B

0.00
0.00 (0.00%)
Share Name Share Symbol Market Type
K V Pharma CL B NYSE:KVB NYSE Ordinary Share
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.00 -

Faruqi & Faruqi, LLP Announces Investigation of K-V Pharmaceutical Company

28/10/2011 9:30pm

Business Wire


K V Pharma CL B (NYSE:KVB)
Historical Stock Chart


From Jun 2019 to Jun 2024

Click Here for more K V Pharma CL B Charts.

Faruqi & Faruqi, LLP, a national law firm concentrating on investor rights, consumer rights and enforcement of federal antitrust laws, is investigating potential wrongdoing at K-V Pharmaceutical Company (“K-V” or the “Company”) (NYSE: KV-A) (NYSE: KV-B). Faruqi & Faruqi, LLP seeks to determine whether certain officers and directors at K-V violated federal securities laws in connection with statements made to the Company's shareholders.

Request more information now by clicking here: www.faruqilaw.com/KV.

The investigation focuses on whether certain individuals violated federal securities laws by, among other things, failing to disclose that: (1) the Company had inaccurately claimed that the Food and Drug Administration (the “FDA”) was granting K-V the exclusive distribution rights over “Makena,” a drug used to prevent miscarriages; (2) the FDA would not be enforcing K-V’s rights by preventing the Company’s competitors from distributing generic formulations of the drug; and (3) the drug’s $1,500 price would reduce the availability of Makena to low-income and other at-risk groups.

On March 30, 2011, the FDA revealed that it did not intend to take enforcement action against K-V’s competitors for distributing generic versions of K-V’s Makena.

Take Action

If you purchased K-V securities between February 14, 2011 and April 4, 2011 and you would like to discuss your legal rights, visit www.faruqilaw.com/KV. You can also contact us by calling Anthony Vozzolo or Richard W. Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to avozzolo@faruqilaw.com or rgonnello@faruqilaw.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding K-V's conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.

About Faruqi & Faruqi, LLP

Faruqi & Faruqi, LLP is a national law firm, representing investors, consumers and companies in the prosecution of claims under state corporate and consumer laws and the federal securities and antitrust laws. The lawyers at Faruqi & Faruqi, LLP have demonstrated a clear commitment to championing the rights of shareholders and consumers nationwide.

Attorney Advertising. (C) 2011 Faruqi & Faruqi, LLP. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

1 Year K V Pharma CL B Chart

1 Year K V Pharma CL B Chart

1 Month K V Pharma CL B Chart

1 Month K V Pharma CL B Chart

Your Recent History

Delayed Upgrade Clock